This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waxman, S. Articles by Anderson, K. C. Search for Related Content PubMed PubMed Citation Articles by Waxman, S. Articles by Anderson, K. C.

History of the Development of Arsenic Derivatives in Cancer Therapy

^a Rochelle Belfer Chemotherapy Foundation Laboratory, Mt. Sinai School of Medicine, New York, New York, USA; ^b Kraft Family Blood Donor Center, Harvard Medical School, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Correspondence: Samuel Waxman, M.D., Rochelle Belfer Chemotherapy Foundation Laboratory, Mt. Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA. Telephone: 212-241-7995; Fax: 212-996-5787; e-mail: waxman{at}msvax.mssm.edu

Arsenic is a natural substance that has been used medicinally for over 2,400 years. In the 19th century, it was the mainstay of the materia medica. A solution of potassium arsenite (Fowler's solution) was used for a variety of systemic illnesses from the 18th until the 20th century. This multipurpose solution was also primary therapy for the treatment of chronic myelogenous leukemia until replaced by radiation and cytotoxic chemotherapy. The past 100 years have seen a precipitous decline in arsenic use and, by the mid-1990s, the only recognized indication was the treatment of trypanosomiasis. Much of this decline was due to concerns about the toxicity and potential carcinogenicity of chronic arsenic administration. The rebirth of arsenic therapy occurred in the 1970s when physicians in China began using arsenic trioxide as part of a treatment for acute promyelocytic leukemia (APL). Their accumulated experience showed that a stable solution of arsenic trioxide given by intravenous infusion was remarkably safe and effective both in patients with newly diagnosed APL leukemia and in those with refractory and relapsed APL. The mechanisms of action of arsenic derivatives in this disease and other malignancies are many and include induction of apoptosis, partial cytodifferentiation, inhibition of proliferation, and inhibition of angiogenesis. Molecular studies and ongoing clinical trials suggest that, as a chemotherapeutic agent, arsenic trioxide shows great promise in the treatment of malignant disease.

Key Words. Arsenic trioxide • Acute promyelocytic leukemia • Apoptosis

This article has been cited by other articles:

				G. M. Lehmann and M. J. McCabe Jr Arsenite Slows S Phase Progression via Inhibition of cdc25A Dual Specificity Phosphatase Gene Transcription Toxicol. Sci., September 1, 2007; 99(1): 70 - 78. [Abstract] [Full Text] [PDF]

				W. Tarello Lymphoid leukaemia in a saker falcon. Vet Rec., February 11, 2006; 158(6): 212 - 212. [Full Text] [PDF]

				N. Karasavvas, J. M. Carcamo, G. Stratis, and D. W. Golde Vitamin C protects HL60 and U266 cells from arsenic toxicity Blood, May 15, 2005; 105(10): 4004 - 4012. [Abstract] [Full Text] [PDF]

				D. Douer and M. S. Tallman Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies J. Clin. Oncol., April 1, 2005; 23(10): 2396 - 2410. [Abstract] [Full Text] [PDF]

				D.-R. Hwang, Y.-C. Tsai, J.-C. Lee, K.-K. Huang, R.-K. Lin, C.-H. Ho, J.-M. Chiou, Y.-T. Lin, J. T. A. Hsu, and C.-T. Yeh Inhibition of Hepatitis C Virus Replication by Arsenic Trioxide Antimicrob. Agents Chemother., August 1, 2004; 48(8): 2876 - 2882. [Abstract] [Full Text] [PDF]

				P. Lunghi, A. Costanzo, M. Levrero, and A. Bonati Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells Blood, July 15, 2004; 104(2): 519 - 525. [Abstract] [Full Text] [PDF]

				T. A. Rich, R. C. Shepard, and S. T. Mosley Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy J. Clin. Oncol., June 1, 2004; 22(11): 2214 - 2232. [Abstract] [Full Text] [PDF]

				J. Liu, C. Li, W. Qu, E. Leslie, C. L. Bonifant, G. S. Buzard, J. E. Saavedra, L. K. Keefer, and M. P. Waalkes Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation Mol. Cancer Ther., June 1, 2004; 3(6): 709 - 714. [Abstract] [Full Text] [PDF]

				R. Wysocki, P.-K. Fortier, E. Maciaszczyk, M. Thorsen, A. Leduc, A. Odhagen, G. Owsianik, S. Ulaszewski, D. Ramotar, and M. J. Tamas Transcriptional Activation of Metalloid Tolerance Genes in Saccharomyces cerevisiae Requires the AP-1-like Proteins Yap1p and Yap8p Mol. Biol. Cell, May 1, 2004; 15(5): 2049 - 2060. [Abstract] [Full Text] [PDF]

				D. Starenki, H. Namba, V. Saenko, A. Ohtsuru, and S. Yamashita Inhibition of Nuclear Factor-{kappa}B Cascade Potentiates the Effect of a Combination Treatment of Anaplastic Thyroid Cancer Cells J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 410 - 418. [Abstract] [Full Text] [PDF]

				Z. He, W.-Y. Ma, G. Liu, Y. Zhang, A. M. Bode, and Z. Dong Arsenite-induced Phosphorylation of Histone H3 at Serine 10 Is Mediated by Akt1, Extracellular Signal-regulated Kinase 2, and p90 Ribosomal S6 Kinase 2 but Not Mitogen- and Stress-activated Protein Kinase 1 J. Biol. Chem., March 14, 2003; 278(12): 10588 - 10593. [Abstract] [Full Text] [PDF]